Sneddon Syndrome (Syndrome, Sneddon)
A systemic non-inflammatory arteriopathy primarily of middle-aged females characterized by the association of LIVEDO RETICULARIS, multiple thrombotic CEREBRAL INFARCTION; CORONARY DISEASE, and HYPERTENSION. Elevation of antiphospholipid antibody titers (see also ANTIPHOSPHOLIPID SYNDROME), cardiac valvulopathy, ISCHEMIC ATTACK, TRANSIENT; SEIZURES; DEMENTIA; and chronic ischemia of the extremities may also occur. Pathologic examination of affected arteries reveals non-inflammatory adventitial fibrosis, thrombosis, and changes in the media (From Jablonski, Dictionary of Syndromes & Eponymic Diseases, 2d ed; Adams et al., Principles of Neurology, 6th ed, p861; Arch Neurol 1997 Jan;54(1):53-60). Mutations in the CECR1 gene (ADA2 protein, human) are associated with Sneddon syndrome.
Also Known As:
Syndrome, Sneddon; Livedo Reticularis And Cerebrovascular Accidents; Sneddon Champion Syndrome; Syndrome, Sneddon-Champion; Livedo Reticularis, Systemic Involvement; Sneddon-Champion Syndrome
Networked: 46
relevant articles (0 outcomes,
2 trials/studies)
Disease Context: Research Results
Related Diseases
Experts
1. | Jiménez-Gallo, David:
2 articles
(01/2016 - 03/2014)
|
2. | Linares-Barrios, Mario:
2 articles
(01/2016 - 03/2014)
|
3. | Cervera, Alvaro:
1 article
(03/2021)
|
4. | Chamorro, Angel:
1 article
(03/2021)
|
5. | Greisenegger, Elli Katharine:
1 article
(03/2021)
|
6. | Greisenegger, Stefan:
1 article
(03/2021)
|
7. | Henes, Jörg:
1 article
(03/2021)
|
8. | Jimenez-Escrig, Adriano:
1 article
(03/2021)
|
9. | Joutel, Anne:
1 article
(03/2021)
|
10. | Kopp, Tamara:
1 article
(03/2021)
|
Drugs and Biologics
Drugs and Important Biological Agents (IBA) related to Sneddon Syndrome:
Therapies and Procedures